東軟熙康(09686.HK)發售價定為每股4.76港元 預計9月28日上市
格隆匯9月27日丨東軟熙康(09686.HK)發佈公吿，公司全球發售約1.338億股股份，其中香港發售股份1199.55萬股，國際發售股份約1.218億股；發售價已釐定為每股股份4.76港元，每手買賣單位500股；中金公司為獨家保薦人；預期股份將於2023年9月28日於聯交所主板掛牌上市。
香港公開發售已接獲合共2299份有效申請，認購合共1199.55萬股香港發售股份，相當於香港公開發售項下初步可供認購的香港發售股份的約0.90倍。國際發售項下初步提呈發售的發售股份已獲小幅超額認購，為國際發售項下初步可供認購發售股份總數的約1.15倍。按發售價每股發售股份4.76港元計算，且根據基石投資協議，基石投資者已認購合共4659.2萬股發售股份。
按發售價每股發售股份4.76港元計算，估計公司將從全球發售中獲得約5.545億港元的所得款項淨額。由於並無對國際發售股份作出超額分配，超額配售權尚未亦將不會獲行使，且預計公司將不會就此收到額外所得款項。公司擬將所得款項淨額約30%用於拓展以城市為入口的雲醫院平台，以擴大公司的醫療網絡及用户羣。公司計劃將公司的雲醫院網絡進一步拓展至新城市，並豐富公司現有以城市為入口的雲醫院平台的服務和能力，從而擴大公司的醫療機構網絡，吸引新用户和維護現有用户；所得款項淨額的約25%將用於豐富公司在整個行業價值鏈上的產品，以提供更專業及多樣化的醫療健康服務。公司擬進一步加強與頂級醫療機構不同領域醫學專家的合作，增強並豐富公司基於醫學專科的服務以滿足患者的多元需求，從而進一步提升彼等的體驗，並擴大公司的雲醫院平台用户基礎；所得款項淨額的約25%將用於技術基礎設施及數據能力的研發。公司計劃持續加強公司平台的技術基礎設施，提升數據處理及安全能力。公司擬加強雲醫院平台的研發投入，以提高平台的安全性、可靠性及靈活性。公司亦計劃不斷將大數據分析、AI及區塊鏈技術融入公司的平台，以進一步加強公司的服務能力；所得款項淨額的約10%在未來3至5年，將用於潛在的併購機會。公司計劃通過戰略合作及併購豐富公司平台上的醫療服務，為醫療系統利益相關方創造更大的價值；所得款項淨額的約10%將用於營運資金及一般公司用途。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
